Why Is Moderna Stock Sinking Thursday?
Key takeaways
- Moderna’s shares plunged after a leaked Phase 3 result suggested a smaller benefit than earlier studies, sparking doubts about the vaccine’s added value.
- 42% risk‑reduction (hazard ratio 0.58) in leaked Phase 3 data
- 49% risk‑reduction in Phase 2b trial
- 59% reduction in distant metastasis or death in Phase 2b
What happened
Moderna Inc. (NASDAQ: MRNA) shares fell more than 25% after an alleged leak of Phase 3 data from its intismeran melanoma vaccine trial, showing a 42% risk‑reduction (hazard ratio 0.58) versus the 49% benefit seen in earlier Phase 2b studies. The leak raised doubts about whether the new vaccine adds value over existing immunotherapy. The companies plan to present full Phase 3 results at the ESMO 2026 Congress.
Why it matters
The drop reflects investors’ concern that the new vaccine’s benefit may be smaller than expected, potentially weakening the case for a high‑priced product. A lower efficacy could limit future sales and affect the company’s valuation, especially given the high cost of developing personalized mRNA therapies. The…
Short-term and longer-term
Short-term. Over the next few days, the stock may continue to wobble as traders digest the leaked numbers and await the official ESMO presentation.
Longer-term. In the months ahead, the vaccine’s long‑term commercial viability hinges on the final Phase 3 outcomes.